CXCR3／CXCL10在乳腺癌中的表达及临床意义  

The expression and clinical significance of CXCR3/CXCL10 in human breast cancer

作　　者：段波峰[1] 郑雏[2] 唐梅徕[2] 范培芝[2] 张超杰[2] 谢靖[2] 李洋[2] 雷珊珊[2] 顾晓文[2] 何杰[2] 

机构地区：[1]湘潭市第一人民医院肿瘤外科,湖南省湘潭411101 [2]湖南省人民医院乳甲外科

出　　处：《中国医师杂志》2011年第10期1305-1308,共4页Journal of Chinese Physician

基　　金：国家自然基金资助项目（20972046）

摘　　要：目的探讨趋化因子受体3（CXCR3）及趋化因子配体10（CXCL10）在乳腺癌中的表达及临床意义。方法采用免疫组织化学SP法及二步法对60例乳腺癌组织、20例乳腺纤维瘤组织及20例乳腺腺病组织分别进行CXCR3、CXCL10检测。结果乳腺癌中CXCR3（40／60，66．7％）、CXCL10（45／60，75％）的表达高于乳腺腺病[CXCR3（8／20，40％）X^2=4．44，P=0．035；CXCL10（10／20，50％）x。=4．36，P=0．037）]，乳腺癌中CXCR3的表达与有无腋窝淋巴结转移、临床分期、HER-2的表达有关（X^2=4．15，P=0．042；X^2=7．74，P：0．021；X^2=4．27，P=0．039），且CXCR3的表达强度与腋窝淋巴结转移数及临床分期目呈正相关（-=0．375，P=0．003；t=0．451，P=0．000）。结论CXCR3可能与乳腺癌的进展及早期转移有关，CXCR3可能作为乳腺癌的一个预后指标。Objective To investigate the expression and clinical significance of CXCR3/CXCL10 in human cancer. Methods CXCR3 and CXCL10 were detected in 60 paraffinic tissues of patients with primary breast cancer, 20 of mammary fibroma and 20 of mastopathy by immunohistochemistry S-P method and two stage method. Results The expression of CXCR3 （40/60,66. 7% ） and CXCL10 （45/60,75%） in breast cancer was higher than that in mastopathy [ CXCR3 （8/20,40%） X^2 = 4.44, P = 0. 035 ; CXCL10 （10/20,50%）X^2 =4. 36, P =0. 037）]. The expression of CXCR3 was related to status of axillary lymph node metastasis, clinical stage and the expression of HER-2 （ X^2 = 4. 15, P = 0. 042 ; X^2 = 7. 74, P = 0. 021 ;X^2 = 4. 27, P = 0. 039）. The expression of CXCR3 had positive relationship to the number axillary lymph node metastasis（ rs = 0. 375, P = 0. 003）, clinical stage （ ri = 0. 451, P = 0. 000）. Conclusions CXCR3 may be related to the progression and metastasis of breast cancer, and it may be used as a marker of breast cancer prognosis.

关 键 词：乳腺肿瘤/代谢 受体 CXCR3/代谢 趋化因子CXCL10/代谢 

分 类 号：R737.9[医药卫生—肿瘤]